# Dimension Bio

> Dimension Bio (formerly Dimension Inx) is a Chicago-based regenerative therapeutics company that turns living cells into implantable, tissue-like therapies. Its BioNidum platform fuses materials science, 3D printing, and digital manufacturing to build three-dimensional microenvironments that help transplanted cells survive, vascularize, and function in the body. A Northwestern University spinout, the company already brought the first FDA-cleared 3D-printed regenerative bone graft (CMFlex) to patients and is now aiming its lead program at acute liver failure - building an engineered, mini-liver-like therapy to stabilize patients and give their own organs a chance to recover.

- **Founded:** 2017
- **Headquarters:** Chicago, Illinois, United States
- **Founders:** Caralynn Nowinski Collens (Co-Founder & CEO), Ramille Shah (Co-Founder, CSO & Head of Platform R&D), Adam Jakus (Co-Founder)
- **Team size:** ~29 employees
- **Products:** BioNidum, Liver Failure Program (lead program), CMFlex, 3D-Paints / biomaterials platform
- **Notable:** Received FDA 510(k) clearance for CMFlex - the first 3D-printed regenerative bone graft product cleared by the FDA., First patients treated with CMFlex via Desktop Health., Spun core biomaterials platform out of Northwestern University.

## Products & services

- **BioNidum** — A bioinspired cell delivery system that fuses materials science, 3D printing, and digital manufacturing to turn cells into implantable, tissue-like therapies. Its 3D architecture promotes rapid vascularization and tissue integration so transplanted cells survive, function, and persist.
- **Liver Failure Program (lead program)** — An engineered, mini-liver-like therapeutic designed to provide immediate supplemental liver function, stabilizing patients in crisis and enabling the native liver to recover - offering an alternative to transplant.
- **CMFlex** — An off-the-shelf, flexible ceramic 3D-printed synthetic bone graft for oral, maxillofacial, mandibular, and dental bone defects. The first 3D-printed regenerative bone graft product cleared by the FDA (510(k)). Commercialized via Desktop Health.
- **3D-Paints / biomaterials platform** — The patented printable biomaterials and manufacturing process originally spun out of Northwestern University, used to fabricate functional tissue and device scaffolds.

## Achievements

- Received FDA 510(k) clearance for CMFlex - the first 3D-printed regenerative bone graft product cleared by the FDA.
- First patients treated with CMFlex via Desktop Health.
- Spun core biomaterials platform out of Northwestern University.
- Closed a $12M Series A led by Prime Movers Lab (Feb 2023).
- Matured the BioNidum cell-delivery platform and established GMP manufacturing.
- Rebranded from Dimension Inx to Dimension Bio to focus on regenerative therapeutics.

## Latest updates

- **2025-11** — Featured by Inc./Fast Company for its plan to develop a simplified, mini-liver-like therapy within roughly three years to keep liver-failure patients alive long enough to recover or reach transplant.
- **2023-02** — Closed $12M Series A and announced FDA clearance of CMFlex in the same period; rebranded toward regenerative therapeutics as Dimension Bio.

## Links

- Website: https://dimension.bio
- LinkedIn: https://www.linkedin.com/company/dimension-inx
- Twitter/X: https://twitter.com/dimensioninx
- Facebook: https://facebook.com/DimensionInx/

---

Profile page: https://yespress.io/dimension-bio
Published by YesPress — https://yespress.io
Last updated: 2026-06-09